Capital Impact Advisors’s 10x Genomics TXG Stock Holding History

Capital Impact Advisors’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13,299	Closed	-$499K	–	97
2024 Q1	$499K	Sell	13,299 -10,295	-44%	-$452K	0.65%	68
2023 Q4	$1.32M	Buy	23,594 +8,773	+59%	+$382K	1.73%	10
2023 Q3	$611K	Buy	14,821 +8,536	+136%	+$444K	1.02%	41
2023 Q2	$351K	Sell	6,285 -370	-6%	-$20K	0.39%	120
2023 Q1	$371K	Buy	6,655 +3,879	+140%	+$181K	0.46%	105
2022 Q4	$101K	Buy	2,776 +580	+26%	+$19K	0.1%	222
2022 Q3	$82K	Buy	+2,196	New	+$83.7K	0.08%	225
2021 Q4	–	Sell	-7,717	Closed	-$1.12M	–	149
2021 Q3	$1.12M	Hold	7,717	–	–	0.45%	93
2021 Q2	$1.51M	Buy	+7,717	New	+$1.4M	0.49%	83

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Impact Advisors's TXG Position: Q2 2024 in Review

Capital Impact Advisors sold out of 10x Genomics (TXG) in Q2 2024, closing a stake of 13,299 shares — an estimated $499K sold.

Capital Impact Advisors first reported a position in TXG in Q2 2021 and held it in 9 quarters. The position peaked at $1.51M in Q2 2021. 261 funds tracked by Wall St. Rank hold TXG as of Q2 2024.

Capital Impact Advisors reported no remaining 10x Genomics position as of Q2 2024 after selling out during the quarter.
Capital Impact Advisors sold 13,299 10x Genomics shares in Q2 2024, an estimated $499K.
Capital Impact Advisors first reported a position in 10x Genomics in Q2 2021 and held it in 9 quarters.
Capital Impact Advisors's 10x Genomics position peaked at $1.51M in Q2 2021.
261 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2024.

Based on Capital Impact Advisors's 13F filing for Q2 2024, filed 16 Aug 2024.